Sanofi Pasteur MSD's Gardasil beating GSK's Cervarix in race to dominate HPV vacc market
Sanofi Pasteur MSD is steaming ahead of GlaxoSmithKline in the race to dominate the new market for vaccines against human papilloma viruses (HPV) causing cervical cancer. Its vaccine Gardasil, with clinical trial data in 25,000 women supporting it, has become the first to launch in Europe after a mere nine-month review period.
The European joint venture, formed 12 years ago by French drug major Sanofi-Aventis and US pharmaceutical giant Merck & Co, hopes to begin launching its vaccine this month in Austria, Sweden, Germany and Finland and, this month, in the UK. Market introductions in Italy, Spain and Greece will follow shortly.
Gardasil was also approved in the USA, Australia, Canada and New Zealand this summer. Already, it has been recommended by the US Centers for Disease Control and Prevention' for routine vaccination of 11-12 year old girls with a catch up program for those over 13 years of age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze